Discounted Cash Flow
Benitec Biopharma Inc. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2019 | $122.0k | $2.6m | $4.4m | 2138.5% | $3.05 |
| 2020 | $102.0k (-16.4%) | $-8.3m (-417.1%) | $-7.6m (-274.0%) | -8111.8% (-479.3%) | $-8.10 (-365.6%) |
| 2021 | $59.0k (-42.2%) | $-13.9m (-67.8%) | $-13.1m (-71.1%) | -23528.8% (-190.1%) | $-3.23 (60.1%) |
| 2022 | $73.0k (23.7%) | $-18.2m (-31.2%) | $-15.9m (-21.9%) | -24942.5% (-6.0%) | $-2.23 (31.0%) |
| 2023 | $75.0k (2.7%) | $-19.6m (-7.4%) | $-18.0m (-13.2%) | -26082.7% (-4.6%) | $-14.12 (-533.2%) |
| 2024 | $904.0k (1105.3%) | $-22.4m (-14.4%) | $-19.6m (-8.7%) | -2474.6% (90.5%) | $-5.51 (61.0%) |
| 2025 | $3.3m (263.5%) | $-37.9m (-69.5%) | $-23.6m (-20.5%) | -1153.9% (53.4%) | $-1.05 (80.9%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.